AANEM News Express

AANEM News Express

Long-term Safety and Efficacy of Mexiletine for Patients With Skeletal Muscle Channelopathies

4/20/2016
 
Suetterlin KJ, Bugiardini E, Kaski JP, et al. Long-term Safety and Efficacy of Mexiletine for Patients With Skeletal Muscle Channelopathies. JAMA Neurol. 2015 Dec 1;72(12):1531-3. 
 
Submitted by Niranjan Singh, MD, News Science Editorial Board
 
Clinical and electrocardiogram data of 63 patients with non-dystrophic myotonias or hyperkalemic periodic paralysis due to CLCN1 or SCN4A mutations treated with mexiletine were analyzed retrospectively. Mexiletine doses ranged between 50 to 600 mg per day. Heart rate, PR interval, QRS duration, and corrected QT interval were calculated for each patient.
Patients with CLCN1 mutations tended to require higher doses of mexiletine as compared to those with SCN4A mutations. No serious adverse were identified with a mean follow up of 4.8 years per patient. Mexiletine did not change any of the cardiac parameters from their baseline measurements. Dyspepsia was the main side effect identified, occurring in 35% of patients.
 
Comment: Neuromuscular physicians often approach mexiletine initiation with trepidation, because the medication may lead to cardiac arrhythmias. No arrhythmias or alterations in EKG parameters were identified in this study, but it should be noted that it was small and retrospective, and vigilance concerning potential arrhythmia should not be relaxed.
 
About the AANEM News Science Editorial Board
 
The board helps to highlight significant, timely science news items for AANEM members. It reviews articles in journals and websites, identifies newsworthy items in the field, and writes article summaries.
 


View Related News Stories:

  Practice


Recent AANEM News

Recap: 2019 AMA House of Delegates Annual Meeting

Science News: Efficacy of Botulinum Toxin A for Treating Cramps in Diabetic Neuropathy

Science News: Diagnostic Sensitivity of Electrophysiology and Ultrasonography in Ulnar Neuropathies of Different Severity

Science News: Long-term Effect of Thymectomy Plus Prednisone Versus Prednisone Alone in Patients with Non-thymomatous Myasthenia Gravis: 2-year Extension of the MGTX Randomised Trial

AANEM Returns to Capitol for 6th Annual Hill Day





Advertisement

TPP

Advertisement

ABEM

Advertisement

Find Your Dream Job